Striatal dopamine transporter binding in early to moderately advanced parkinson’s disease: Monitoring of disease progression over 2 years

Nuclear Medicine Communications

Volumn 22, Issue 6, 2001, Pages 721-725

  Chouker, M ^a   Tatsch, K ^a   Linke, R ^a   Pogarell, O ^a   Hahn, K ^a   Schwarz, J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Dopamine transporter binding; IPT; Parkinson s disease; Rate of progression

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; N (3 IODOPROPEN 2 YL) 2BETA CARBOMETHOXY 3BETA (4 CHLOROPHENYL)TROPANE; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DISEASE SEVERITY; DRUG BINDING; DRUG UPTAKE; FOLLOW UP; HUMAN; PARKINSON DISEASE; PATIENT MONITORING; PROTEIN BINDING; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TECHNIQUE;

ADULT; AGED; CARRIER PROTEINS; CAUDATE NUCLEUS; DISEASE PROGRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEOSTRIATUM; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PUTAMEN; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0034982492     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200106000-00017     Document Type: Review

References (21)

1. Marsden CD. Parkinson’s disease. J Neurol Neurosurg Psychiatr 1994; 57: 672-681.
2. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1991; 321: 1364-1371.
3. 18F-dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain 1996; 119: 585-591.
4. Innis RB, Seibyl JP, Scanley BE et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson’s disease. Proc Natl Acad Sci USA 1993; 90: 11965-11969.
5. Kuikka JT, Bergström KA, Vanninen E, Laulumaa V, Hartikainen P, Länsimies E. Initial experience with single-photon emission tomography using iodine-123-labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane in human brain. Eur J Nucl Med 1993; 20: 783-786.
6. 123I]-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 1996; 46: 231-237.
7. Tatsch K, Schwarz J, Mozley PD et al. Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter binding assessed with (I-123)IPT and SPECT. Eur J Nucl Med 1997; 24: 415-421.
8. Marek KL, Seibyl J, Fussel B, Cellar J, Smith E, Innis R. 123I-β-CIT: assessment of progression in Parkinson’s disease. Neurology 1997; 48(Suppl. A): 207-208.
9. Booij J, Winogrodzka A, Bergmans P, Wolters EC, Stoof JC, Royen EA. [I-123] β-CIT and [I-123] FP-CIT SPECT are useful methods to monitor progression of dopaminergic degeneration in early-stage Parkinson’s disease. J Nucl Med 1999; 40: 28P.
10. Seibyl JP, Innis RB, Early ML, Fussell BA, Marek K. Baseline striatal dopamine transporter uptake measured with [I-123] β-CIT SPECT may predict rate of disease progression in idiopathic Parkinson’s disease. J Nucl Med 1999; 40: 27P.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr 1992; 55: 181-184.
12. Kung M-P, Essmann WD, Frederick D et al. IPT: a novel iodinated ligand for the CNS dopamine transporter. Synapse 1995; 20: 316-324.
13. Mozley PD, Stubbs JB, Kim H-J et al. Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J Nucl Med 1996; 37: 151-159.
14. 18F]CFT. Ann Neurol 2000; 47: 804-808.
15. Linke R, Gostomzyk J, Hahn K, Tatsch K. [I-123]IPT-binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med 2000; 27: 1809-1812.
16. Seibyl JP, Marek K, Sheff K et al. Test/retest reproducibility of iodine-123-βCIT SPECT brain measurement of dopamine transporters in Parkinson’s patients. J Nucl Med 1997; 38: 1453-1459.
17. Vingerhoets FJG, Schulzer M, Ruth TJ, Holden JE, Snow BJ. Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson’s disease. J Nucl Med 1996; 37: 421-426.
18. Mozley PD, Kim HJ, Gur RC et al. Iodine-123 IPT SPECT imaging of CNS dopamine transporters: nonlinear effects of normal aging on striatal uptake values. J Nucl Med 1996; 37: 1965-1970.
19. 123I]β-CIT. Mov Disord 1999; 14: 436-442.
20. Ahlskog JE, Uitti RJ, O’Connor MK et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson’s disease. Mov Disord 1999; 14: 940-946.
21. 123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. Eur J Nucl Med 2000; 27: 346-349.